Designing novel building blocks is an overlooked strategy to improve compound quality

Drug Discovery Today

Volumn 20, Issue 1, 2015, Pages 11-17

  Goldberg, Frederick W ^a   Kettle, Jason G ^a   Kogej, Thierry ^b   Perry, Matthew W D ^b   Tomkinson, Nick P ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

REAGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG QUALITY; MEDICINAL CHEMISTRY; PRACTICE GUIDELINE; REVIEW; CHEMISTRY;

DRUG DESIGN; INDICATORS AND REAGENTS;

EID: 84921457580     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.09.023     Document Type: Review

References (42)

1. Yusof, I. and Segall, M.D. (2013) Considering the impact drug-like properties have on the chance of success. Drug Discov. Today 18, 659-666
2. Bickerton, G.R. et al. (2012) Quantifying the chemical beauty of drugs. Nat. Chem. 4, 90-98
3. Leeson, P.D. and Springthorpe, B. (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6, 881-890
4. Tarcsay, A. et al. (2012) Impact of lipophilic efficiency on compound quality. J. Med. Chem. 55, 1252-1260
5. Cumming, J.G. et al. (2013) Chemical predictive modelling to improve compound quality. Nat. Rev. Drug Discov. 12, 948-962
6. Waring, M.J. (2010) Lipophilicity in drug discovery. Expert Opin. Drug Discov. 5, 235-248
7. Ritchie, T.J. and Macdonald, J.F. (2014) How drug-like are 'ugly' drugs: do drug-likeness metrics predict ADME behaviour in human? Drug Discov. Today 19, 489-495
8. Stocks, M.J. et al. (2009) Practical method for targeted library design balancing lead-like properties with diversity. Chem. Med. Chem. 4, 800-808
9. Schamberger, J. et al. (2011) Rendezvous in chemical space? Comparing the small molecule compound libraries of Bayer and Schering. Drug Discov. Today 16, 636-641
10. Nicholls, A. et al. (2010) Molecular shape and medicinal chemistry: a perspective. J. Med. Chem. 53, 3862-3886
11. Kogej, T. et al. (2013) Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case. Drug Discov. Today 18, 1014-1024
12. Rosen, J. et al. (2009) Novel chemical space exploration via natural products. J. Med. Chem. 52, 1953-1962
13. Constantino, L. and Barlocco, D. (2006) Privileged structures as leads in medicinal chemistry. Curr. Med. Chem. 13, 65-85
14. Ritchie, T.J. et al. (2012) The developability of heteroaromatic and heteroaliphatic rings: do some have a better pedigree as potential drug molecules than others? Med. Chem. Commun. 3, 1062-1069
15. St Jean, D.J. and Fotsch, C. (2012) Mitigating heterocycle metabolism in drug discovery. J. Med. Chem. 55, 6002-6020
16. Goldberg, F.W. (2014) Design of novel reagent sets to enhance drug discovery. 247th ACS National Meeting, Dallas, TX, USA, MEDI-29
17. Ward, R.A. and Kettle, J.G. (2011) Systematic enumeration of heteroaromatic ring systems as reagents for use in medicinal chemistry. J. Med. Chem. 54, 4670-4677
18. Kettle, J.G. et al. (2010) Data-mining patent literature for novel chemical reagents for use in medicinal chemistry design. Med. Chem. Commun. 1, 331-338
19. Marino, S.T. et al. (2004) Synthesis of chiral building blocks for use in drug discovery. Molecules 9, 405-426
20. Lovering, F. et al. (2009) Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752-6756
21. Meanwell, N.A. (2011) Synopsis of some recent tactical application of bioisosteres in drug design. J. Med. Chem. 54, 2529-2591
22. Lücking, U. (2013) Sulfoximines: a neglected opportunity in medicinal chemistry. Angew. Chem. Int. Ed. 52, 9399-9408
23. Goldberg, F.W. et al. (2014) General synthetic strategies towards N-alkyl sulfoximine building blocks for medicinal chemistry and the use of dimethylsulfoximine as a versatile precursor. Tetrahedron http://dx.doi.org/10.1016/j.tet.2014.06.120
24. Wang, J. and Hou, T. (2010) Drug and drug candidate building block analysis. J. Chem. Inf. Model. 50, 55-67
25. Goldberg, F.W. et al. (2012) Free-Wilson and structural approaches to co-optimizing human and rodent isoform potency for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors. J. Med. Chem. 55, 10652-10661
26. Yngve, U. et al. (2013) Triazolopyrimidinones as gamma-secretase modulators: structure-activity relationship, modulator profile, and in vivo profiling. Med. Chem. Commun. 4, 422-431
27. Lipinski, C.A. et al. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25
28. Oprea, T.I. et al. (2001) Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41, 1308-1315
29. Congreve, M. et al. (2003) 'Rule of three' for fragment-based lead discovery? Drug Discov. Today 8, 876-877
30. Nadin, A. et al. (2012) Lead-oriented synthesis: a new opportunity for synthetic chemistry. Angew. Chem. Int. Ed. 51, 1114-1122
31. Liu, K.K. et al. (2011) Synthetic approaches to the 2009 new drugs. Bioorg. Med. Chem. 19, 1136-1154
32. Liu, K.K. et al. (2012) Synthetic approaches to the 2010 new drugs. Bioorg. Med. Chem. 20, 1155-1174
33. Ding, H.X. et al. (2013) Synthetic approaches to the 2011 new drugs. Bioorg. Med. Chem. 21, 2795-2825
34. Ding, H.X. et al. (2014) Synthetic approaches to the 2012 new drugs. Bioorg. Med. Chem. 22, 2005-2032
35. Carey, J.S. et al. (2006) Analysis of the reactions used for the preparation of drug candidate molecules. Org. Biomol. Chem. 4, 2337-2347
36. Roughley, S.D. and Jordan, A.M. (2011) The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. J. Med. Chem. 54, 3451-3479
37. Cooper, T.W.J. et al. (2010) Factors determining the selection of organic reactions by medicinal chemists and the use of these reactions in arrays (small focused libraries). Angew. Chem. Int. Ed. 49, 8082-8091
38. Hartenfeller, M. et al. (2012) Probing the bioactivity-relevant chemical space of robust reactions and common molecular building blocks. J. Chem. Inf. Model. 52, 1167-1178
39. Xing, L. et al. (2014) Scaffold mining of kinase hinge binders in crystal structure database. J. Comput. Aided Mol. Des. 28, 13-23
40. Schuhmacher, A. et al. (2013) Models for open innovation in the pharmaceutical industry. Drug Discov. Today 18, 1133-1137
41. Alvim-Gaston, M. et al. (2014) Open innovation drug discovery (OIDD): a potential path to novel therapeutic chemical space. Curr. Top. Med. Chem. 14, 294-303
42. Judd, D.B. (2013) Open innovation and intellectual property: time for a reboot? Drug Discov. Today 18, 907-909